Navigation Links
West Announces Third Quarter 2009 Results
Date:11/3/2009

-GAAP September 30, Brazil Tax Tax September 30, 2009 Restructuring Amnesty benefits 2009 ---- ------------- ------- -------- ---- Operating profit $75.8 $1.1 $(3.9) $- $73.0 Interest expense, net 10.5 - - - 10.5 ---- -- -- -- ---- Income before income taxes 65.3 1.1 (3.9) - 62.5 Income tax expense 14.6 0.4 (2.2) 2.1 14.9 Equity in net income of affiliated companies 1.6 - - - 1.6 --- -- -- -- --- Net income 52.3 0.7 (1.7) (2.1) 49.2 Less: net income attributable to noncontrolling interests - - - - - -- -- -- -- -- Net income attributable to common shareholders $52.3 $0.7 $(1.7) $(2.1) $49.2 ----- ---- ----- ----- ----- Net income per diluted share attributable to common shareholders $1.53 $0.02 $(0.04) $(0.06) $1.45 ----- ----- ------ ------ ----- WEST PHARMACEUTICAL SERVICES NON-GAAP MEASURES (UNAUDITED) NINE MONTHS ENDED SEPTEMBER 30, 2008 (in millions, except per share data) Contract As Reported settlement Non-GAAP September 30,
'/>"/>
SOURCE West Pharmaceutical Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 1Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 2Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 3Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 1Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 2Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 1Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 2Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 3
Breaking Medicine News(10 mins):Health News:Thomson Reuters Releases Micromedex 2.0 2Health News:Thomson Reuters Releases Micromedex 2.0 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Recognized Top Performers in UHC Supply Chain 2
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: